Mega-blockbuster obesity drug!

The market for mega-blockbuster obesity drugs has finally opened in our country. The development of the next generation of oral GLP-1 agonists has been challenging. The limitations of mid-molecular drug discovery by mimicking bioactive peptides are also becoming apparent. However, the entry of big pharma is expected to continue in the future.
https://miyata-bio.net/column/0000303/